Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of vibegron versus placebo in men with overactive bladder symptoms receiving pharmacologic therapy for benign prostatic hyperplasia
2018-003135-30Phase 3Completed
- Sponsor
- Urovant Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Vibegron with Placebo (2 arms). Primary endpoint: Change from baseline in average number of micturition episodes per day. Started May 2019; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2018-003135-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003135-30.